For most of medical history, Alzheimer’s disease could only be diagnosed after symptoms appeared—often years after the underlying biology had already begun damaging the brain.
Today, that is starting to change.
New laboratory tests are allowing clinicians to detect early signs of neurodegeneration using a simple Alzheimer’s blood test. These tests measure proteins released into the bloodstream when brain cells are stressed, inflamed, or injured. The goal isn’t to diagnose dementia in healthy people. Instead, it’s to identify whether the biological processes that lead to Alzheimer’s may already be underway—often 20–30 years before symptoms develop.
This earlier window matters. When we detect changes early, we have more opportunity to intervene.
At Aya Naturopathic Medicine, we view these biomarkers as one tool within a larger cognitive health assessment, sometimes called a cognoscopy—a comprehensive evaluation of brain health risk and resilience.
Below we’ll explain how these tests work, who may benefit from them, and how they fit into a broader strategy for protecting long-term brain health.
Why an Alzheimer’s Blood Test Matters
Research over the past two decades has shown that Alzheimer’s disease develops long before memory loss begins.
The earliest biological changes include:
• accumulation of amyloid plaques
• formation of tau tangles inside neurons
• inflammation and injury to brain cells
• gradual loss of synaptic connections
These processes can begin two or even three decades before symptoms appear (Jack et al., 2013).
Traditionally, detecting these changes required PET brain scans or spinal taps, which are expensive, invasive, and not widely available.
A modern Alzheimer’s blood test can provide a much simpler way to screen for some of these biological signals. These tests measure proteins released into the bloodstream as the brain responds to injury or neurodegeneration.
It’s important to understand what these tests can and cannot do.
They do not diagnose Alzheimer’s disease on their own. Instead, they help clinicians estimate whether Alzheimer’s-related pathology may be present and whether additional evaluation is warranted.
The Three Biomarkers in an Alzheimer’s Blood Test
Several blood markers are currently used to evaluate brain health. Each reflects a different biological process involved in neurodegeneration.
GFAP: A Marker of Brain Inflammation
GFAP (glial fibrillary acidic protein) is a protein found in astrocytes, the support cells that help protect neurons.
When the brain becomes inflamed or stressed, astrocytes become activated and release GFAP into the bloodstream.
Elevated GFAP may indicate:
• neuroinflammation
• early response to amyloid plaque formation
• astrocyte activation in neurodegenerative disease
In several studies, GFAP appears to rise very early in the Alzheimer’s process, sometimes even before measurable tau changes (Chatterjee et al., 2021).
For this reason, some researchers consider GFAP one of the earliest shifting blood biomarkers in Alzheimer’s disease.
Neurofilament Light Chain (NfL): A Marker of Neuronal Injury
Neurofilament light chain (NfL) is a structural protein found inside neurons.
When neurons are damaged, fragments of NfL leak into cerebrospinal fluid and eventually into the bloodstream.
Elevated NfL suggests:
• active neurodegeneration
• axonal injury
• progression of neurological disease
NfL is not specific to Alzheimer’s—it can also rise in conditions such as multiple sclerosis, traumatic brain injury, and ALS.
However, higher levels are consistently associated with faster cognitive decline and greater brain atrophy in Alzheimer’s disease (Mattsson et al., 2017).
p-Tau181: A Marker of Alzheimer’s-Specific Tau Pathology
Tau proteins help stabilize the internal structure of neurons. In Alzheimer’s disease, abnormal phosphorylated tau (p-tau) forms tangles that disrupt cell function.
The p-Tau181 blood test measures a specific phosphorylated form of tau strongly associated with Alzheimer’s pathology.
Elevated p-Tau181 levels suggest:
• formation of tau tangles
• likely presence of amyloid plaques in the brain
• Alzheimer’s-specific neurodegeneration
In 2025, the U.S. Food and Drug Administration cleared the Elecsys pTau181 plasma test to help clinicians evaluate Alzheimer’s pathology in adults with cognitive symptoms (Alzheimer’s Association, 2025).
Importantly, this test is intended as a clinical aid, not a stand-alone diagnosis.
Which Alzheimer’s Blood Test Changes First?
If someone could only run one marker, the question often becomes: Which biomarker changes earliest?
Current research suggests a rough sequence:
-
GFAP rises first (early neuroinflammation)
-
p-Tau increases (tau pathology)
-
NfL increases (neuron injury and degeneration)
This sequence reflects the biological cascade of Alzheimer’s disease: inflammation and amyloid changes occur first, followed by tau pathology and eventual neuron loss.
However, no single marker provides a complete picture. Most experts recommend a panel approach rather than relying on one test alone.
Who Might Consider an Alzheimer’s Blood Test?
An Alzheimer’s blood test is not currently recommended as a routine screening tool for the general population.
However, in specialty clinics focused on cognitive decline prevention, these biomarkers may be used as part of a broader evaluation called a cognoscopy—a term popularized by neurologist Dr. Dale Bredesen to describe a comprehensive brain health assessment.
As a physician trained in the RECODE protocol (Reversal of Cognitive Decline), I sometimes recommend these tests for patients who are undergoing a detailed cognitive health evaluation.
Situations where testing may be considered include:
• individuals with subjective cognitive decline or mild cognitive symptoms
• people with a strong family history of Alzheimer’s disease
• patients seeking a proactive brain health assessment in midlife
• individuals already undergoing a cognoscopy to evaluate Alzheimer’s risk
These tests help us determine whether biological processes associated with neurodegeneration may already be present, allowing us to tailor prevention strategies more precisely.
An Alzheimer’s Blood Test Is Only One Piece of the Puzzle
Even the best biomarker cannot tell the whole story.
At our clinic, cognitive health evaluations look at many modifiable risk factors known to influence Alzheimer’s risk.
These include:
• chronic inflammation
• blood sugar regulation and insulin resistance
• cholesterol and vascular health
• hormone balance
• sleep quality
• nutrient status
• toxin exposure
• stress and mental health
We also evaluate cognitive function directly through validated assessments.
Together, these elements form a comprehensive brain health evaluation known as a cognoscopy.
The goal is not simply to detect disease.
The goal is to identify opportunities for prevention and reversal.
Why Early Detection Matters
One of the most important insights in modern neurology is this:
Alzheimer’s disease develops slowly—and that means we have time to act.
Many of the drivers of neurodegeneration are modifiable:
• inflammation
• metabolic dysfunction
• sleep disorders
• vascular disease
• nutrient deficiencies
In a landmark proof-of-concept study of a precision medicine approach to Alzheimer’s disease, 84% of participants experienced measurable cognitive improvement after addressing these underlying contributors (Bredesen et al., 2016).
While more large-scale trials are still underway, these findings support the idea that cognitive decline may not always be irreversible, particularly when intervention begins early.
An Alzheimer’s blood test does not determine your future. Instead, it provides information about whether certain biological processes may be starting.
And when we know sooner, we can act sooner.
A Balanced Perspective
These tests represent an exciting advance in medicine—but they are still evolving.
Even with FDA clearance of some assays, experts emphasize that blood biomarkers should be used as part of a broader clinical evaluation, not as stand-alone diagnostic tools (Hansson et al., 2022).
Our goal in sharing this information is not to persuade anyone to pursue testing.
It is simply to provide clear, balanced information about emerging tools that may help people better understand and protect their brain health.
In a world where Alzheimer’s disease often feels inevitable, knowledge can be empowering.
And sometimes the most powerful intervention is simply learning early enough to change the trajectory.
If you are interested in learning more about whether a cognoscopy and Alzheimer’s screening might be appropriate for you, book a discovery call with me using this link.
References
Alzheimer’s Association. (2025). FDA clearance of the Elecsys pTau181 plasma test for Alzheimer’s disease assessment.
Bredesen, D. E., Amos, E. C., Canick, J., et al. (2016). Reversal of cognitive decline in Alzheimer’s disease. Aging, 8(6), 1250–1258.
Chatterjee, P., Pedrini, S., Stoops, E., et al. (2021). Plasma glial fibrillary acidic protein is elevated in Alzheimer’s disease and predicts cognitive decline. Alzheimer’s & Dementia, 17(4), 695–706.
Hansson, O., et al. (2022). Blood biomarkers for Alzheimer’s disease in clinical practice: Recommendations from the Alzheimer’s Association. Nature Reviews Neurology, 18, 111–120.
Jack, C. R., Knopman, D. S., Jagust, W. J., et al. (2013). Tracking pathophysiological processes in Alzheimer’s disease: An updated hypothetical model. Lancet Neurology, 12(2), 207–216.
Mattsson, N., Andreasson, U., Zetterberg, H., & Blennow, K. (2017). Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurology, 74(5), 557–566.
